(19)

(11)

EP 4 561 629 A2

(12)

(88) Date of publication A3: 11.07.2024 (43) Date of publication: 04.06.2025 Bulletin 2025/23 (21) Application number: 23886770.9 (22) Date of filing: 24.07.2023

(51) International Patent Classification (IPC):  A61K 45/06(2006.01) A61P 35/00(2006.01) A61K 51/08(2006.01) (52) Cooperative Patent Classification (CPC): A61K 51/0497; A61K 51/0468; A61K 31/55; A61K 45/06   C-Sets: A61K 31/55, A61K 2300/00; (86) International application number: PCT/US2023/070835 (87) International publication number: WO 2024/097446 (10.05.2024 Gazette 2024/19)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA Designated Validation States: KH MA MD TN (30) Priority: 25.07.2022 US 202263391905 P (71) Applicant: Cytosite Biopharma Inc. Sudbury, MA 01776-1946 (US)	(72) Inventors: BILCER, Geoffrey Malcolm Shorewood, Minnesota 55331 (US) KRONAUGE, James Sudbury, Massachusetts 01776-1946 (US) (74) Representative: Larsen, Charles et al McDermott Will Emery LLC 22 Bishopsgate London EC2N 4BQ London EC2N 4BQ (GB)